Elanco Australasia has lost its bid to appeal a finding by IP Australia that a patent acquired from Bayer covering a lice treatment for livestock lacked an inventive step.
Petrol chain United Petroleum has sued competitor On The Run for allegedly wrongly claiming its ‘Quickstop’ and ‘Cigmart’ marks infringe On The Run’s trade marks.
A judge has granted Australian bubble tea franchise Sharetea a third adjournment of a trial in a $10 million case brought by its Taiwanese franchisor, despite “very significant concern” that Sharetea’s director did not do everything in his power to find new lawyers in time.
An IP Australia delegate has shot down Apple’s application to patent a touchscreen interface used on its electronic devices, calling the invention a “logistical scheme” for organising media files rather than a technological innovation.
Cargill has won a trade mark infringement case against a company that a judge said appeared to be operating an “internet scam” to intercept a $10 million payment to the multinational food company.
A three-year court battle over PepsiCo’s Monster Munch trade mark has been resolved, with Monster Energy negotiating the removal of some beverage products that would have been covered by the mark.C
The Iconic has defeated a challenge to the online fashion retailer’s application to trade mark ‘Considered’ for sustainable or ethically sourced products, with IP Australia rejecting Net-a-Porter’s argument that the label has not been used in the sense required under the Trade Marks Act.
The High Court has declined to step in after Hells Angels’ award of $78,000 in damages for online marketplace Redbubble’s infringement of its trade marks was slashed to just $100, bringing to an end an IP fight that has stretched on for nearly a decade.
Fortescue has brought legal action against start-up Element Zero and three former employees, alleging “industrial scale misuse” of the Western Australian mining company’s confidential information.
Drug giant Pfizer has blasted Samsung Bioepis’ “fishing expedition” in its suit alleging infringement of the patent for its blockbuster arthritis drug Enbrel, telling the court the Korean biotech should not be allowed to dig for new grounds of invalidity.